Details:
X-Chem will screen its unique DNA-encoded libraries against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute these hits into transformational medicines for degenerative disease.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: X-Chem
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 05, 2023
Details:
The successful completion of this fundraising is a testimony to team's ability to accomplish CNS drug development and jump starts the discovery engine to build a pipeline with AAV-based gene therapy and small molecule programs.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: LAPAM
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 29, 2022
Details:
During the three-year collaboration, multiple undisclosed targets (including undruggable targets) were screened against HitGen’s proprietary DNA encoded chemical libraries (DELs). The majority of the targets have resulted in confirmed novel potent hits.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Mitsubishi Tanabe Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 25, 2022